anti-TF ADC
Adcendo Secures $1 Billion Deal for Multitude’s Anti-TF ADC
Adcendo, Multitude Therapeutics, anti-TF ADC, $1 billion deal, biobucks, antibody-drug conjugate, cancer treatment
Actionable Insights Powered by AI
Adcendo, Multitude Therapeutics, anti-TF ADC, $1 billion deal, biobucks, antibody-drug conjugate, cancer treatment